Key result
In older patients with advanced CKD, serum potassium exhibited a U-shaped relationship with death or KRT start, with highest risks at ≤3.5 mmol/L (HR 1.6) and >6.0 mmol/L (HR 2.2).
Why the study?
Little is known about the relationship between serum potassium and death or the occurrence of kidney failure requiring replacement therapy in older people with CKD stage 4-5.
Do abnormal serum potassium levels increase the risk of death or kidney replacement therapy in older patients with CKD stages 4-5?
Cohort (n=1,714)
Yes
Do abnormal serum potassium levels increase the risk of death or kidney replacement therapy in older patients with CKD stages 4-5?
Hazard Ratio: 2.2 (95% CI 1.5–3.3)
Both low and high serum potassium levels are associated with an increased risk of death or kidney replacement therapy in older patients with advanced CKD, with an optimal nadir at 4.9 mmol/L.
Supports vigilance for potassium abnormalities in older advanced CKD patients; leaves open optimal targets for prospective trials.
RATIONALE & OBJECTIVE: Hypokalemia may accelerate kidney function decline. Both hypo- and hyperkalemia can cause sudden cardiac death. However, little is known about the relationship between serum potassium and death or the occurrence of kidney failure requiring replacement therapy (KRT). We investigated this relationship in older people with chronic kidney disease (CKD) stage 4-5. STUDY DESIGN: Prospective observational cohort study. SETTING & PARTICIPANTS: measurement. EXPOSURE: Serum potassium was measured every 3 to 6 months and categorized as≤3.5,>3.5-≤4.0,>4.0-≤4.5,>4.5-≤5.0 (reference),>5.0-≤5.5, >5.5-≤6.0, and>6.0mmol/L. OUTCOME: The combined outcome death before KRT or start of KRT. ANALYTICAL APPROACH: The association between categorical and continuous time-varying potassium and death or KRT start was examined using Cox proportional hazards and restricted cubic spline analyses, adjusted for age, sex, diabetes, cardiovascular disease, renin-angiotensin-aldosterone system (RAAS) inhibition, eGFR, and subjective global assessment (SGA). RESULTS: , and mean SGA was 6.0±1.0 (SD). Over 8 years, 414 (24%) died before starting KRT, and 595 (35%) started KRT. Adjusted hazard ratios for death or KRT according to the potassium categories were 1.6 (95% CI, 1.1-2.3), 1.4 (95% CI, 1.1-1.7), 1.1 (95% CI, 1.0-1.4), 1 (reference), 1.1 (95% CI, 0.9-1.4), 1.8 (95% CI, 1.4-2.3), and 2.2 (95% CI, 1.5-3.3). Hazard ratios were lowest at a potassium of about 4.9mmol/L. LIMITATIONS: Shorter intervals between potassium measurements would have allowed for more precise estimations. CONCLUSIONS: We observed a U-shaped relationship between serum potassium and death or KRT start among patients with incident CKD 4-5, with a nadir risk at a potassium level of 4.9mmol/L. These findings underscore the potential importance of preventing both high and low potassium in patients with CKD 4-5. PLAIN-LANGUAGE SUMMARY: Abnormal potassium blood levels may increase the risk of death or kidney function decline, especially in older people with chronic kidney disease (CKD). We studied 1,714 patients aged≥65 years with advanced CKD from the European Quality (EQUAL) study and followed them for 8 years. We found that both low and high levels of potassium were associated with an increased risk of death or start of kidney replacement therapy, with the lowest risk observed at a potassium level of 4.9 mmol/L. In patients with CKD, the focus is often on preventing high blood potassium. However, this relatively high optimum potassium level stresses the potential importance of also preventing low potassium levels in older patients with advanced CKD.
No takes yet. Share an insight, caveat, or question.
Rooij et al. (2023) conducted a cohort in Chronic kidney disease (CKD) stage 4-5 (n=1,714). Serum potassium vs. >4.5-≤5.0 mmol/L was evaluated on Death before KRT or start of KRT (HR 2.2, 95% CI 1.5-3.3). In older patients with advanced CKD, serum potassium exhibited a U-shaped relationship with death or KRT start, with highest risks at ≤3.5 mmol/L (HR 1.6) and >6.0 mmol/L (HR 2.2).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: